Development and characterization of bladder cancer patient- derived xenografts for molecularly guided targeted therapy

Chong Xian Pan, Hongyong Zhang, C. G. Tepper, Tzu Yin Lin, Ryan R. Davis, James Keck, Paramita M. Ghosh, Parkash Gill, Susan Airhart, Carol Bult, David R. Gandara, Edison Liu, Ralph W. De Vere White

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background The overarching goal of this project is to establish a patientderived bladder cancer xenograft (PDX) platform, annotated with deep sequencing and patient clinical information, to accelerate the development of new treatment options for bladder cancer patients. Herein, we describe the creation, initial characterization and use of the platform for this purpose. Methods and Findings Twentytwo PDXs with annotated clinical information were established from uncultured unselected clinical bladder cancer specimens in immunodeficient NSG mice. The morphological fidelity was maintained in PDXs. Whole exome sequencing revealed that PDXs and parental patient cancers shared 92-97% of genetic aberrations, including multiple druggable targets. For drug repurposing, an EGFR/HER2 dual inhibitor lapatinib was effective in PDX BL0440 (progressionfree survival or PFS of 25.4 days versus 18.4 days in the control, p = 0.007), but not in PDX BL0269 (12 days versus 13 days in the control, p = 0.16) although both expressed HER2. To screen for the most effective MTT, we evaluated three drugs (lapatinib, ponatinib, and BEZ235) matched with aberrations in PDX BL0269; but only a PIK3CA inhibitor BEZ235 was effective (p<0.0001). To study the mechanisms of secondary resistance, a fibroblast growth factor receptor 3 inhibitor BGJ398 prolonged PFS of PDX BL0293 from 9.5 days of the control to 18.5 days (p<0.0001), and serial biopsies revealed that the MAPK/ERK and PIK3CAAKT pathways were activated upon resistance. Inhibition of these pathways significantly prolonged PFS from 12 day of the control to 22 days (p = 0.001). To screen for effective chemotherapeutic drugs, four of the first six PDXs were sensitive to the cisplatin/gemcitabine combination, and chemoresistance to one drug could be overcome by the other drug. Conclusion The PDX models described here show good correlation with the patient at the genomic level and known patient response to treatment. This supports further evaluation of the PDXs for their ability to accurately predict a patient's response to new targeted and combination strategies for bladder cancer.

Original languageEnglish (US)
Article numbere0134346
JournalPLoS One
Volume10
Issue number8
DOIs
StatePublished - Aug 13 2015

Fingerprint

Heterografts
Urinary Bladder Neoplasms
therapeutics
drugs
Pharmaceutical Preparations
gemcitabine
Aberrations
Receptor, Fibroblast Growth Factor, Type 3
Therapeutics
Drug Repositioning
Biopsy
Exome
High-Throughput Nucleotide Sequencing
cisplatin
MAP Kinase Signaling System
Cisplatin
urinary bladder neoplasms
biopsy
genomics
neoplasms

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Development and characterization of bladder cancer patient- derived xenografts for molecularly guided targeted therapy. / Pan, Chong Xian; Zhang, Hongyong; Tepper, C. G.; Lin, Tzu Yin; Davis, Ryan R.; Keck, James; Ghosh, Paramita M.; Gill, Parkash; Airhart, Susan; Bult, Carol; Gandara, David R.; Liu, Edison; De Vere White, Ralph W.

In: PLoS One, Vol. 10, No. 8, e0134346, 13.08.2015.

Research output: Contribution to journalArticle

Pan, Chong Xian ; Zhang, Hongyong ; Tepper, C. G. ; Lin, Tzu Yin ; Davis, Ryan R. ; Keck, James ; Ghosh, Paramita M. ; Gill, Parkash ; Airhart, Susan ; Bult, Carol ; Gandara, David R. ; Liu, Edison ; De Vere White, Ralph W. / Development and characterization of bladder cancer patient- derived xenografts for molecularly guided targeted therapy. In: PLoS One. 2015 ; Vol. 10, No. 8.
@article{b8fbf368e43549f19a6beb04c7d2e317,
title = "Development and characterization of bladder cancer patient- derived xenografts for molecularly guided targeted therapy",
abstract = "Background The overarching goal of this project is to establish a patientderived bladder cancer xenograft (PDX) platform, annotated with deep sequencing and patient clinical information, to accelerate the development of new treatment options for bladder cancer patients. Herein, we describe the creation, initial characterization and use of the platform for this purpose. Methods and Findings Twentytwo PDXs with annotated clinical information were established from uncultured unselected clinical bladder cancer specimens in immunodeficient NSG mice. The morphological fidelity was maintained in PDXs. Whole exome sequencing revealed that PDXs and parental patient cancers shared 92-97{\%} of genetic aberrations, including multiple druggable targets. For drug repurposing, an EGFR/HER2 dual inhibitor lapatinib was effective in PDX BL0440 (progressionfree survival or PFS of 25.4 days versus 18.4 days in the control, p = 0.007), but not in PDX BL0269 (12 days versus 13 days in the control, p = 0.16) although both expressed HER2. To screen for the most effective MTT, we evaluated three drugs (lapatinib, ponatinib, and BEZ235) matched with aberrations in PDX BL0269; but only a PIK3CA inhibitor BEZ235 was effective (p<0.0001). To study the mechanisms of secondary resistance, a fibroblast growth factor receptor 3 inhibitor BGJ398 prolonged PFS of PDX BL0293 from 9.5 days of the control to 18.5 days (p<0.0001), and serial biopsies revealed that the MAPK/ERK and PIK3CAAKT pathways were activated upon resistance. Inhibition of these pathways significantly prolonged PFS from 12 day of the control to 22 days (p = 0.001). To screen for effective chemotherapeutic drugs, four of the first six PDXs were sensitive to the cisplatin/gemcitabine combination, and chemoresistance to one drug could be overcome by the other drug. Conclusion The PDX models described here show good correlation with the patient at the genomic level and known patient response to treatment. This supports further evaluation of the PDXs for their ability to accurately predict a patient's response to new targeted and combination strategies for bladder cancer.",
author = "Pan, {Chong Xian} and Hongyong Zhang and Tepper, {C. G.} and Lin, {Tzu Yin} and Davis, {Ryan R.} and James Keck and Ghosh, {Paramita M.} and Parkash Gill and Susan Airhart and Carol Bult and Gandara, {David R.} and Edison Liu and {De Vere White}, {Ralph W.}",
year = "2015",
month = "8",
day = "13",
doi = "10.1371/journal.pone.0134346",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Development and characterization of bladder cancer patient- derived xenografts for molecularly guided targeted therapy

AU - Pan, Chong Xian

AU - Zhang, Hongyong

AU - Tepper, C. G.

AU - Lin, Tzu Yin

AU - Davis, Ryan R.

AU - Keck, James

AU - Ghosh, Paramita M.

AU - Gill, Parkash

AU - Airhart, Susan

AU - Bult, Carol

AU - Gandara, David R.

AU - Liu, Edison

AU - De Vere White, Ralph W.

PY - 2015/8/13

Y1 - 2015/8/13

N2 - Background The overarching goal of this project is to establish a patientderived bladder cancer xenograft (PDX) platform, annotated with deep sequencing and patient clinical information, to accelerate the development of new treatment options for bladder cancer patients. Herein, we describe the creation, initial characterization and use of the platform for this purpose. Methods and Findings Twentytwo PDXs with annotated clinical information were established from uncultured unselected clinical bladder cancer specimens in immunodeficient NSG mice. The morphological fidelity was maintained in PDXs. Whole exome sequencing revealed that PDXs and parental patient cancers shared 92-97% of genetic aberrations, including multiple druggable targets. For drug repurposing, an EGFR/HER2 dual inhibitor lapatinib was effective in PDX BL0440 (progressionfree survival or PFS of 25.4 days versus 18.4 days in the control, p = 0.007), but not in PDX BL0269 (12 days versus 13 days in the control, p = 0.16) although both expressed HER2. To screen for the most effective MTT, we evaluated three drugs (lapatinib, ponatinib, and BEZ235) matched with aberrations in PDX BL0269; but only a PIK3CA inhibitor BEZ235 was effective (p<0.0001). To study the mechanisms of secondary resistance, a fibroblast growth factor receptor 3 inhibitor BGJ398 prolonged PFS of PDX BL0293 from 9.5 days of the control to 18.5 days (p<0.0001), and serial biopsies revealed that the MAPK/ERK and PIK3CAAKT pathways were activated upon resistance. Inhibition of these pathways significantly prolonged PFS from 12 day of the control to 22 days (p = 0.001). To screen for effective chemotherapeutic drugs, four of the first six PDXs were sensitive to the cisplatin/gemcitabine combination, and chemoresistance to one drug could be overcome by the other drug. Conclusion The PDX models described here show good correlation with the patient at the genomic level and known patient response to treatment. This supports further evaluation of the PDXs for their ability to accurately predict a patient's response to new targeted and combination strategies for bladder cancer.

AB - Background The overarching goal of this project is to establish a patientderived bladder cancer xenograft (PDX) platform, annotated with deep sequencing and patient clinical information, to accelerate the development of new treatment options for bladder cancer patients. Herein, we describe the creation, initial characterization and use of the platform for this purpose. Methods and Findings Twentytwo PDXs with annotated clinical information were established from uncultured unselected clinical bladder cancer specimens in immunodeficient NSG mice. The morphological fidelity was maintained in PDXs. Whole exome sequencing revealed that PDXs and parental patient cancers shared 92-97% of genetic aberrations, including multiple druggable targets. For drug repurposing, an EGFR/HER2 dual inhibitor lapatinib was effective in PDX BL0440 (progressionfree survival or PFS of 25.4 days versus 18.4 days in the control, p = 0.007), but not in PDX BL0269 (12 days versus 13 days in the control, p = 0.16) although both expressed HER2. To screen for the most effective MTT, we evaluated three drugs (lapatinib, ponatinib, and BEZ235) matched with aberrations in PDX BL0269; but only a PIK3CA inhibitor BEZ235 was effective (p<0.0001). To study the mechanisms of secondary resistance, a fibroblast growth factor receptor 3 inhibitor BGJ398 prolonged PFS of PDX BL0293 from 9.5 days of the control to 18.5 days (p<0.0001), and serial biopsies revealed that the MAPK/ERK and PIK3CAAKT pathways were activated upon resistance. Inhibition of these pathways significantly prolonged PFS from 12 day of the control to 22 days (p = 0.001). To screen for effective chemotherapeutic drugs, four of the first six PDXs were sensitive to the cisplatin/gemcitabine combination, and chemoresistance to one drug could be overcome by the other drug. Conclusion The PDX models described here show good correlation with the patient at the genomic level and known patient response to treatment. This supports further evaluation of the PDXs for their ability to accurately predict a patient's response to new targeted and combination strategies for bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=84942874576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942874576&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0134346

DO - 10.1371/journal.pone.0134346

M3 - Article

C2 - 26270481

AN - SCOPUS:84942874576

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e0134346

ER -